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Safety of Statins
Focus on Clinical Pharmacokinetics and Drug Interactions
Stefano Bellosta, PhD; Rodolfo Paoletti, MD, PhD; Alberto Corsini, PhD
Abstract—Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important
adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of
which occur infrequently. Because statins are prescribed on a long-term basis, however, possible interactions with other
drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant
conditions during the course of statin treatment. This review summarizes the pharmacokinetic properties of statins and
emphasizes their clinically relevant drug interactions.(Circulation. 2004;109[suppl III]:III-50–III-57.)
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The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are a well-established
class of drugs in the treatment of hypercholesterolemia, and
members of this class have been shown to reduce the risk of
cardiovascular morbidity and mortality in patients with or at
risk for coronary heart disease (CHD)1,2 in several clinical
trials. These trials have largely dispelled doubt about the
safety and tolerability of statins. In fact, the common adverse
effects associated with statin therapy are relatively mild and
often transient (gastrointestinal symptoms, headache, rash).1,3
The most important adverse effects associated with statins
(atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin,
and simvastatin) are asymptomatic increases in liver
transaminases and myopathy. Based on this clinical evidence,
the U.S. National Cholesterol Education Program (NCEP)
Adult Treatment Panel (ATP) III report3 extended the use of
lipid-lowering treatments to a larger number of high-risk
CHD patients who often receive more than one medication.
Therefore, the potential for drug–drug interactions emerges
as a relevant factor in determining the safety profile of statins.
Pharmacological differences are evident among the statins,
however, and these may affect their safety and potential for
drug interactions.4 Moreover, as pointed out in a recent
adverse-event report from the U.S. Food and Drug Adminis-
tration (FDA),5 the incidence of side effects might be higher
in clinical situations in which patients are not monitored as
closely as in clinical trials. The worldwide withdrawal of
cerivastatin in August 2001 because of its association with
fatal rhabdomyolysis further underscores the importance of
considering the safety profile of the available statins.6 The
purpose of this article is to increase awareness of differences
that could help clinicians in selecting the appropriate statin
for long-term treatment of their patients.
Liver Transaminase Elevations
During initial postmarketing surveillance of statins, eleva-
tions in hepatic transaminases were reported at incidences of
up to 1%;1,7 these elevations were dose related and compa-
rable among the various statins, although not significantly
increased compared with placebo.7 The majority of liver
abnormalities occur within the first 3 months of therapy and
require monitoring.
Myopathy
The term “myopathy” designates any noninherited disorder of
skeletal muscle that causes proximal muscle weakness, with
difficulty in arising from a chair or raising arms above the
head.8 Duration of statin therapy before the onset of myop-
athy varies from a few weeks to more than 2 years.9
Statin-associated myopathy represents a broad clinical spec-
trum of disorders, from mild muscle aches to severe pain and
restriction in mobility, with grossly elevated creatine kinase
(CK) levels.8 However, patients have been described who
developed these symptoms while receiving statin therapy
despite normal serum CK levels, thus pointing out the
inadequacy of CK testing for statin-associated myopathy.10,11
In statin clinical trials, the reported incidence of myopathy
was low (0.1 to 0.2%).8,12 The symptoms progress toward
rhabdomyolysis as long as patients continue to take the drug.
Rhabdomyolysis is a syndrome that results from severe
skeletal muscle injury and lysis, causing the widespread
release of myoglobin with dark brown urine secondary to
myoglobinuria.1,8 An analysis of data from the Adverse Event
Reporting System (AERS) of the FDA showed that as of June
2001, fatal rhabdomyolysis had been reported at rates of 1
death per 1 million prescriptions for all statins, except
cerivastatin, which had an incidence of 3 deaths per 1
million prescriptions.6
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It should be noted that the development of myopathy is
induced by a complex interaction between drug, disease,
genetics, and concomitant therapy.4,7 Several risk factors that
predispose patients to myopathy include increased age, fe-
male gender, renal or liver disease, diabetes mellitus, hypo-
thyroidism, debilitated status, surgery, trauma, excessive
alcohol intake, and heavy exercise.13 The mechanism by
which statins cause myopathy is not completely understood.
However, the clinical association appears to be dose depen-
dent, and the risk is known to increase when statins are
prescribed in combination with agents that are also myotoxic
when used as monotherapy or that increase the serum
concentration of the statin.4,14 For example, one study re-
ported an 0.15% incidence of myopathy with lovastatin
monotherapy, which increased to 2%, 5%, and 28%, respec-
tively, in patients receiving concomitant niacin, gemfibrozil,
or cyclosporine plus gemfibrozil.9 A review by Omar and
Wilson5 of all reports of statin-associated cases reported to
the FDA (between November 1997 and March 2001) showed
a total of 817 reports and 601 cases of rhabdomyolysis
associated with all statins available at that time. As shown in
Table 1, in 55% of all cases, a drug–drug interaction was
suspected.5 A more extensive FDA search on statin-
associated rhabdomyolysis, covering the period from January
TABLE 1. Profile of Reports of Rhabdomyolysis Associated With Statins
Statin
Frequency of
Reports/Unique Cases
No. of Cases Associated With Potentially Interacting
Drugs* (n)
Simvastatin 321/215 Mibefradil (48) Azole antifungals (4)
Fibrates (33) Chlorzoxazone (2)
Cyclosporine (31) Nefazodone (2)
Warfarin (12) Niacin (2)
Macrolide antibiotics (10) Tacrolimus (1)
Digoxin (9) Fusidic acid (1)
Cerivastatin 231/192 Fibrates (22)
Digoxin (7)
Warfarin (6)
Macrolide antibiotics (2)
Cyclosporine (1)
Mibefradil (1)
Atorvastatin 105/73 Mibefradil (45)
Fibrates (10)
Macrolide antibiotics (13)
Warfarin (7)
Cyclosporine (5)
Digoxin (5)
Azole antifungals (2)
Pravastatin 98/71 Fibrates (6)
Macrolide antibiotics (6)
Warfarin (5)
Cyclosporine (2)
Digoxin (2)
Mibefradil (1)
Niacin (1)
Lovastatin 51/40 Cyclosporine (12) Digoxin (2)
Macrolide antibiotics (11) Nefazodone (2)
Azole antifungals (6) Niacin (1)
Fibrates (5) Warfarin (1)
Mibefradil (3)
Fluvastatin 11/10 Fibrates (4)
Warfarin (2)
Digoxin (1)
Mibefradil (1)
*Each case may be associated with 1 or more potentially interacting drugs.
Adapted from Omar MA, Wilson JP. Ann Pharmacother. 2002;36:288–295.
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1990 through March 2002, showed that among 3339 reports
of rhabdomyolysis, 58% of the cases were associated with
concomitant medications affecting statin metabolism, includ-
ing mibefradil, fibrates, cyclosporine, macrolides, warfarin,
digoxin, and azole antifungals.15 The incidence of fatal
rhabdomyolysis has been estimated using databases from the
FDA and is low, resulting in only 0.15 deaths per 1 million
prescriptions. This figure uses as the denominator the number
of prescriptions, not the number of individuals using the
medication.15 Clinical trial results support a low incidence of
severe muscle problems with statin therapy. A compilation of
all randomized controlled statin trials revealed that among
83 858 patients randomly assigned to receive either statin
treatment or placebo, there were only 49 cases of myositis
and 7 cases of rhabdomyolysis in the statin groups, compared
with 44 cases of myositis and 5 cases of rhabdomyolysis in
the placebo groups.15 However, these results in volunteer
study participants who were monitored by lipid researchers
may underestimate the incidence when statins are used in
unselected populations monitored with less precision.15 Thus,
although there are significant limitations to the interpretation
of the reported adverse events, this information has valuable
implications for clinical practice.
Drug Interactions With Statins: Focus on
Pharmacokinetic Differences
To understand the molecular bases of statin–drug interac-
tions, it is important to mention that statins are very selective
inhibitors of HMG-CoA reductase and usually do not show
any relevant affinity toward other enzymes or receptor
systems.4 This suggests that, at the pharmacodynamic level
(ie, at their site of action), statins are not prone to interfere
with other drugs. However, at the pharmacokinetic level (ie,
absorption, distribution, metabolism, and excretion of a given
drug), the available statins have important differences, in-
cluding half-life, systemic exposure, maximum plasma con-
centration (Cmax), bioavailability, protein binding, lipophilic-
ity, metabolism, presence of active metabolites, and excretion
routes (Table 2).4,16 The liver biotransforms all statins, which
accounts for their overall low systemic bioavailability. The
apparent total body clearance is very high because of an
important hepatic first-pass effect. With the exception of
pravastatin, which is transformed enzymatically in the liver
cytosol, all statins undergo extensive microsomal metabolism
by the cytochrome P450 (CYP) isoenzyme systems (Table 3).
About half of all drugs currently available in clinical practice
are biotransformed in the liver primarily by the CYP450 3A4
system.17 The CYP3A4 isoenzyme is responsible for the
metabolism of lovastatin, simvastatin, and atorvastatin. Flu-
vastatin is metabolized primarily by the CYP2C9 enzyme,
with CYP3A4 and CYP2C8 contributing to a lesser extent.4
Rosuvastatin is not extensively metabolized, but has some
interaction with the CYP2C9 enzyme.16
These differences can affect the potential for drug interac-
tions with statins,4 which can result in markedly increased or
decreased plasma concentrations of some drugs within this
class. Concomitant use of certain drugs (fibrates, erythromy-
cin, itraconazole, and immunosuppressive drugs such as
cyclosporine) can increase blood levels of statins and, con-
sequently, the risk for myopathy.18 The relationship between
altered plasma concentrations and adverse effects or toxicity
might not be linear.10,19 Other variables that affect this
concentration–effect relationship include rapid changes in the
concentrations, concomitant lipid-lowering therapy, or host
genetic factors that code for different forms or amounts of
metabolizing enzymes and drug receptors. Special popula-
tions at high risk for cardiovascular disease, such as patients
with coronary heart disease, dyslipidemia, diabetes, hyperten-
sion, nephrotic disease, human immunodeficiency virus
(HIV) infection, organ transplant patients, and the elderly,
should receive particular attention to avoid clinically relevant
interactions. However, because statins have different pharma-
cological properties, some statins may be more or less likely
than others to cause drug interactions.4 Nevertheless, the
incidence of both myopathy and rhabdomyolysis with statins
is quite low, despite the common coprescription of these
agents with competing substrates or inhibitors of their me-
tabolism.20,21 Indeed, up to one third of prescriptions issued
for statins were in combination with drugs that could poten-
TABLE 2. Clinical Pharmacokinetics of HMG-CoA Reductase Inhibitors
Parameter Atorvastatin Fluvastatin Fluvastatin XL Lovastatin Pravastatin Rosuvastatin Simvastatin
Tmax (h) 2–3 0.5–1 4 2–4 0.9–1.6 3 1.3–2.4
Cmax (ng/mL) 27–66 448 55 10–20 45–55 37 10–34
Bioavailability (%) 12 19–29 6 5 18 20 5
Lipophilicity Yes Yes Yes Yes No No Yes
Protein binding (%) 80–90 99 99 95 43–55 88 94–98
Metabolism CYP3A4 CYP2C9 CYP2C9 CYP3A4 Sulfation CYP2C9, 2C19 (minor) CYP3A4
Metabolites Active Inactive Inactive Active Inactive Active (minor) Active
Transporter protein
substrates
Yes No No Yes Yes/No Yes Yes
T1/2 (h) 15–30 0.5–2.3 4.7 2.9 1.3–2.8 20.8 2–3
Urinary excretion (%) 2 6 6 10 20 10 13
Fecal excretion (%) 70 90 90 83 71 90 58
Based on a 40-mg oral dose, with the exception of fluvastatin XL (80 mg).
Adapted from data in Corsini A, et al. Pharmacol Ther. 1999;84:413–428, and White CM. J Clin Pharmacol. 2002;42:963–970.
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tially interact with them, although side effects occurred in
only 3% of these patients.22
Statin Interactions With CYP450 Inhibitors
Induction or inhibition of CYP450 isoenzymes is an impor-
tant cause of drug interactions.4 Competitive inhibition be-
tween drugs at the enzymatic level is common and may serve
to alter the disposition of statins, leading to increased plasma
levels and greater risk of adverse events (Table 4). Pharma-
cokinetic interactions (eg, increased bioavailability) resulting
in myositis and rhabdomyolysis have been reported after
concurrent use of statins and several different classes of drugs
(Table 5).4,5,23–26
Fluvastatin, which is primarily metabolized by CYP2C9,
and pravastatin and rosuvastatin, which are eliminated by
other metabolic routes, are less subject to this interaction than
other statins. Nevertheless, a 5- to 23-fold increase in prava-
statin bioavailability has been reported in the presence of
cyclosporine A.4,27 It has been postulated that competition for
carrier-mediated transport across the bile canalicular mem-
brane between pravastatin and cyclosporine leads to a re-
duced biliary clearance of pravastatin.4 A cyclosporine–pra-
vastatin interaction may occur also at the level of the transport
protein P-glycoprotein.4 FDA adverse-events reports on
statin-associated rhabdomyolysis5 and postmarketing surveil-
lance28 have confirmed an increased risk of myopathy when
pravastatin is combined with cyclosporine (Table 1). This
suggests that cyclosporine may interact with statins via
mechanisms not limited to CYP3A4 inhibition. On the other
hand, fluvastatin shows a far milder interaction with cyclo-
sporine, most likely because fluvastatin is primarily recog-
nized by CYP2C9 rather than CYP3A4.4 These findings
provided a rationale for the Assessment of Lescol in Renal
Transplantation (ALERT) trial in renal transplanted patients
TABLE 3. Human Cytochrome P450 Isoenzymes Known to Oxidize Clinically Used Drugs
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A4
Acetaminophen Alprenolol Diazepam Amitriptyline Acetaminophen Amiodarone
Caffeine Diclofenac Ibuprofen Codeine Etanol Atorvastatin
Theophylline Fluvastatin Mephenytoin Debrisoquine Halothane Clarithromycin
Hexobarbital Methylphenobarbital Flecainide Cyclosporine
Phenytoin Omeprazole Imipramine Diltiazem
Tolbutamide Phenytoin Metoprolol Erythromycin
Warfarin Proguanyl Mibefradil Itraconazole
Nortriptyline Ketoconazole
Pherexiline Lacidipine
Propafenone Lovastatin
Propranolol Mibefradil
Sparteine Midazolam
Thioridazine Nefazodone
Timolol Nifedipine
Protease inhibitors
Quinidine
Sildenafil
Simvastatin
Terbinafine
Verapamil
Warfarin
TABLE 4. Inhibitors and Inducers of the Cytochrome P450 Enzymatic Pathway
CYP Substrates (Statins) Inducers Inhibitors
CYP3A4
Atorvastatin, lovastatin, simvastatin Phenytoin, phenobarbital, barbiturates, rifampin,
dexamethasone, cyclophosphamide,
carbamazepine, troglitazone, omeprazole
Ketoconazole, itraconazole, fluconazole,
erythromycin, clarithromycin, tricyclic
antidepressants, nefazodone, venlafaxine,
fluvoxamine, fluoxetine, sertraline, cyclosporine A,
tacrolimus, mibefradil, diltiazem, verapamil,
protease inhibitors, midazolam, corticosteroids,
grapefruit juice, tamoxifen, amiodarone
CYP2C9
Fluvastatin, rosuvastatin (2C19-minor) Rifampin, phenobarbital, phenytoin, troglitazone Ketoconazole, fluconazole, sulfaphenazole
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with hypercholesterolemia who were treated with cyclospor-
ine and randomized to receive either fluvastatin or placebo.29
Adverse-event rates were similar in both treatment groups, as
were rates of discontinuation because of adverse events. The
incidence of alanine aminotransferase elevations 3 times
the upper limit of normal (ULN) or CK elevations 5 times
the ULN was similar in fluvastatin-treated and placebo-
treated patients, and no elevations were accompanied by
musculoskeletal symptoms. The safety profile is perhaps the
most remarkable aspect of this trial, as all the renal transplant
patients enrolled were taking cyclosporine, 80% were taking
prednisone, and 95% received concomitant cardiovascular
medications.29 However, caution should be exercised when
fluvastatin is combined with substrates for CYP2C9. For
example, potentiation of the anticoagulant effects of warfa-
rin,4 and increased bioavailability, peak plasma concentra-
tions, and plasma half-life of fluvastatin have been reported
when fluvastatin is coadministered with diclofenac and
fluconazole.30,31
Dyslipidemia, one of the major metabolic abnormalities
associated with HIV infection, appears to be related to the use
of protease inhibitors, due to increased hepatic triglyceride
synthesis.32 Statins are being used increasingly in HIV-
infected patients. However, cases of myalgia, rhabdomyoly-
sis, and transaminase elevations have been reported with
statins26,33 because of the fact that protease inhibitors also
inhibit the CYP3A4/5 isoenzymes (Table 3).
Finally, inhibitors of CYP3A4 isoenzyme activity, such as
cimetidine and grapefruit juice, increase the oral availability
and pharmacokinetic parameters of statins, thus potentially
increasing their systemic exposure and side effects. In partic-
ular, the administration of 200 mL of double-strength grape-
fruit juice 3 times a day for 2 days, followed on day 3 by the
administration of lovastatin together with 200 mL of juice,
and additional doses of 200 mL 30 minutes and 90 minutes
after statin intake, increased the lovastatin concentration–time
curve (AUC) and Cmax 15-fold and 12-fold, respectively.34
The same experiment was performed with simvastatin, and
the AUC and Cmax increased 16-fold and 9-fold, respective-
ly.35 However, despite the high concentrations of simvastatin
and simvastatin acid when coadministered with grapefruit
juice, the HMG-CoA reductase inhibitory activity AUC and
Cmax increased only from 3-fold to 5-fold.35 Under the same
experimental conditions, grapefruit juice significantly in-
creased up to 3.3-fold the AUC of atorvastatin, whereas no
changes were observed in the pharmacokinetics of pravasta-
tin.36 The interaction potential of even high amounts of
grapefruit juice with CYP3A4 substrates dissipates within 3
to 7 days after ingestion of the last dose of juice.37 However,
daily consumption of a glass of regular-strength grapefruit
juice has a minimal effect on plasma statin concentrations
(approximately 30% to 40% increase) after a 40-mg evening
dose of lovastatin.38 It may be concluded that the interaction
between grapefruit juice and statins does not represent a great
concern, unless 1 quart per day of juice is consumed.37
Statins and Calcium Antagonists
Many patients with hypercholesterolemia also have high
blood pressure and may be receiving antihypertensive therapy
with calcium channel antagonists. Of particular note is the
interaction of statins with mibefradil, which was withdrawn
from the global market because of a range of serious
drug–drug interactions.4 Several cases of statin-associated
rhabdomyolysis were reported in patients receiving
mibefradil.39
Both verapamil and diltiazem, which are weak inhibitors of
CYP3A4,28 increase the plasma concentration of simvastatin
up to 4-fold, and diltiazem increases the plasma concentration
of lovastatin to the same magnitude.40,41 Cases of rhabdomy-
olysis have also been reported with the association of dilti-
azem with atorvastatin or simvastatin,42,43 suggesting a need
for some caution in using these agents simultaneously.
Statin Interactions With CYP450 Inducers
Cytochrome P450 inducers (Table 4) may decrease statin
plasma levels. This seems to be the case with troglitazone
(now withdrawn from the U.S. market), a thiazolidinedione
antidiabetic agent that induces the CYP3A4 enzyme.44 Anal-
ogously, it has been shown that rifampicin, another inducer,
greatly decreases the plasma concentrations of simvastatin.45
Phenytoin, another inducer of CYP3A4, can alter the
lipid-lowering efficacy of both atorvastatin and simvastatin.46
It has also been reported that the herbal supplement St. John’s
wort decreases plasma concentrations of simvastatin but not
of pravastatin;47 this interaction most likely is caused by the
enhancement of the CYP3A4-mediated first-pass metabolism
of simvastatin in the small intestine and liver by this herbal
supplement.
Interactions Between Statins and Fibric
Acid Derivatives
The interaction of statins with fibrates deserves particular
attention because myopathy can occur with either drug alone,
and the effects may be additive.4 The rate of fatal rhabdomy-
olysis was 16 to 80 times higher with the withdrawn statin,
cerivastatin, than with the other statins then in clinical use;
this difference appears to be related to the marked interaction
(relative to that of other statins) between cerivastatin and
gemfibrozil.6 A review13 of 36 published clinical trials
involving statin–fibrate combination therapy and 29 case
TABLE 5. Selected Drugs That May Increase Risk of Myopathy
and Rhabdomyolysis When Used Concomitantly With Statins
CYP3A4 Inhibitors/Substrates Others
Cyclosporine, tacrolimus Digoxin
Macrolides (azithromycin, clarithromycin,
erythromycin)
Fibrates (gemfibrozil)
Azole antifungals (itraconazole, ketoconazole) Niacin
Calcium antagonists (mibefradil, diltiazem,
verapamil)
Nefazodone
Protease inhibitors (amprenavir, indinavir,
nelfinavir, ritonavir, saquinavir)
Sildenafil
Warfarin
Adapted from Corsini A, et al. Pharmacol Ther. 1999;84:413–428.
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reports of rhabdomyolysis found that the prevalence of
myopathy associated with statin–fibrate combination therapy
was 0.12%. Although all fibrates have been associated with
cases of CK elevations and myopathy in combination with
statins, the risk for the development of myopathy may be
greater for gemfibrozil compared with bezafibrate or fenofi-
brate. The concomitant use of gemfibrozil and atorvastatin,
lovastatin, pravastatin, or simvastatin has been associated
with case reports of rhabdomyolysis.5,48,49
It is generally believed that the adverse effects of
combination therapy with a statin plus a fibrate is based on
pharmacodynamic interactions. However, gemfibrozil was
shown to increase plasma concentrations of active simva-
statin and lovastatin acid forms but minimally the lactone
forms, whereas bezafibrate demonstrated no significant
effect on the pharmacokinetics of lovastatin. Recently, it
was shown that gemfibrozil can modulate the pharmaco-
kinetics of statins more via inhibition of statin hydroxy
acid glucuronidation than via inhibition of CYP3A4-
mediated oxidation.50 Glucuronidation is a previously
unrecognized, but common, metabolic pathway for the
conversion of active open acid forms of several statins
(including atorvastatin and rosuvastatin) to their lactone
form. The lactone form, in turn, plays a critical role in the
subsequent statin metabolism catalyzed by CYP3A4.51
Consistent with the severe interactions reported with
gemfibrozil, cerivastatin was shown to be more susceptible
than simvastatin and atorvastatin to metabolic interaction
with gemfibrozil at the level of glucuronidation.50 Addi-
tionally, a potential difference between gemfibrozil and
fenofibrate in their ability to alter the pharmacokinetics of
statins has been shown in human hepatocytes in which
fenofibrate was much less effective than gemfibrozil in
affecting simvastatin metabolism.50 Finally, the interaction
between gemfibrozil and pravastatin could occur at the
transport protein level.52 Altogether, these studies provide
a possible explanation for the difference in the interactions
observed among various statin–fibrate combinations.
Statin–fibrate combination therapy should be undertaken
cautiously and reserved for patients with severe or refractory
hyperlipidemia. In addition, because fibrates may impair liver
function, which could lead to higher plasma levels of statins,
patients with impaired liver function should not receive this
combination. Furthermore, mild renal impairment may in-
crease the risk of myopathy because fibrates are primarily
excreted renally.
Other Statin Interactions
Changes in the absorption and excretion of drugs independent
of CYP metabolism can alter drug disposition and may
contribute to the interaction potential of statins. A newly
recognized class of active drug transporters, including the
P-glycoproteins,4,53 is known to affect the disposition and
bioavailability of many drugs, including CYP3A4 substrates.
Transport proteins are, at least in part, responsible for the low
and variable oral bioavailability of atorvastatin, lovastatin,
simvastatin, and pravastatin (Table 2).54 Indeed, interactions
with other drugs at the P-glycoprotein level could potentially
be responsible for the rhabdomyolysis observed after statin–
digoxin combination therapy. Digoxin is a P-glycoprotein
substrate/inhibitor, and its narrow therapeutic range makes
any drug–drug interaction important, warranting the moni-
toring of digoxin levels. In fact, acute interactions have been
observed with simvastatin,55 and coadministration of atorva-
statin 80 mg/d and digoxin 0.25 mg/d for 20 days increased
systemic exposure to digoxin by inhibition of P-glycopro-
tein.56 However, administration of atorvastatin 10 mg/d with
digoxin did not affect mean steady-state concentrations of
digoxin.56 Rosuvastatin, but not fluvastatin, has been shown
to be recognized by these transporters.14,16
Clinical trials in which patients have received niacin in
combination with fluvastatin, pravastatin, or simvastatin have
also not reported myopathy,4,57,58 although the number of
patients in these trials was low. However, in case reports,
niacin has been associated with rhabdomyolysis in combina-
tion with lovastatin, pravastatin, or simvastatin, but not with
atorvastatin or fluvastatin.4,5,9 A lovastatin and extended-
release niacin combination product has recently become
available, and no cases of myopathy have been reported in an
open-label study with this combination.59 No clinically im-
portant interactions have been observed between statins and
other drugs used in cardiovascular diseases, such as propran-
olol, angiotensin-converting enzyme inhibitors, and thiazide
diuretics.
An interaction also may occur between statins and
antithrombotic agents.4 The administration of statins to
patients receiving warfarin caused a small potentiation of
the anticoagulant effect, requiring a warfarin dosage re-
duction, and a recent FDA report has documented cases of
rhabdomyolysis when all statins were given in combina-
tion with warfarin.5 The mechanism underlying the inter-
action between statins and warfarin is due to a competition
at the cytochrome level.4
Finally, evidence suggests that genetic polymorphisms
play a potentially key role in the efficacy, safety, and
tolerability of all medications.60 For example, findings indi-
cate that CYP2D6 polymorphisms influence the efficacy and
tolerability of simvastatin.61
Conflicting data have been reported on the effect of statins
on clopidogrel-inhibited platelet aggregation in patients un-
dergoing coronary stenting; at the moment, there are no clear
reasons to exclude the coadministration of these two classes
of drugs in patients who are at high risk for coronary
events.62–65
Conclusion
The safety and tolerability of statins supports their use as
first-line treatment for hypercholesterolemia. Myopathy and
its serious complication, rhabdomyolysis, are a potential
effect of therapy with the available statins, but occur very
rarely. The molecular and biochemical mechanisms of my-
opathy and rhabdomyolysis caused by statins are yet to be
fully elucidated. Appropriate awareness and attention to the
potential for myopathy with statin therapy, in particular when
they are given in combination with other drugs, should reduce
the risk of this adverse event considerably. The different
pharmacokinetic profiles among the statins should be care-
fully considered to understand the different spectrum of drug
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interactions. These interactions are important determinants of
safety in patients with hypercholesterolemia, especially in
those requiring long-term therapy with drugs that are well-
known CYP3A4 substrates and/or inhibitors.
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